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Epidemiology of Cancers in Zambia: A significant 





Cancer is one of  the leading causes of  death worldwide. More than two-thirds of  deaths due to cancers occur in low- and middle- 
income countries where Zambia belongs. This study, therefore, sought to assess the epidemiology of  various types of  cancers in 
Zambia.
Methods
We conducted a retrospective observational study using the Zambia National Cancer Registry (ZNCR) population based data from 
2007 to 2014. Zambia Central Statistics Office (CSO) demographic data were used to determine catchment area denominator used to 
calculate prevalence and incidence rates of  cancers. Age-adjusted rates and case fatality rates were estimated using standard methods. 
We used a Poisson Approximation for calculating 95% confidence intervals (CI). 
Results
The seven most cancer prevalent districts in Zambia were Luangwa, Kabwe, Lusaka, Monze, Mongu, Katete and Chipata. Cervical 
cancer, prostate cancer, breast cancer and Kaposi’s sarcoma were the four most prevalent cancers as well as major causes of  cancer 
related deaths in Zambia. Age adjusted rates and 95% CI for these cancers were: cervix uteri (186.3; CI = 181.77 – 190.83), prostate 
(60.03; CI = 57.03 – 63.03), breast (38.08; CI = 36.0 – 40.16) and Kaposi’s sarcoma (26.18; CI = 25.14 – 27.22). CFR were: Leukaemia 
(38.1%); pancreatic cancer (36.3%); lung cancer (33.3%); and brain, nervous system (30.2%). The cancer population was associated 
with HIV with p- value of  0.000 and a Pearson correlation coefficient of  0.818.
Conclusions
The widespread distribution of  cancers with high prevalence observed in the southern zone may have been perpetrated by lifestyle and 
sexual culture (traditional male circumcision known to prevent STIs is practiced in the northern belt) as well as geography. Intensifying 
cancer screening and early detection countrywide as well as changing the lifestyle and sexual culture would greatly help in the reduction 
of  cancer cases in Zambia.
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Introduction
The global burden of  cancer has been on the increase over 
the past few decades despite some remarkable advances 
in treatment and prevention1. Cancer continues to be one 
of  the leading causes of  death worldwide. This has driven 
scientists to make advancements in conventional medicine 
as well as anticancer nanomedicine and nanotechnology to 
broaden the spectrum of  combating the scourge2-4. In the 
year 2017, cancers caused over 9.6 million deaths worldwide 
and  moved from the third leading cause of  death in 1990 to 
the second leading cause behind cardiovascular diseases5-7. 
More than two - thirds of  deaths due to cancers occur in 
low- and middle- income countries8. Low-income countries 
reported approximately 51% of  all cancers globally in the 
year 1975 but this proportion steadily increased to 55% in 
2007. It is estimated that by 2050, low-income countries will 
account for 61% of  all cancers globally9-11.
The global increase in the number of  cancer cases is 
due to multiple factors, which include: lifestyle factors 
(smoking, alcohol, lack of  physical exercise, poor/unhealthy 
diet, environmental factors (exposure to carcinogens), 
socioeconomic status and infectious agents12-15. Developing 
countries have 26% cancers attributable to infection while 
developed countries have 8% which is a third of  those in 
developing countries16. The oncogenic infections that have 
been linked to these cancers are Human Papilloma Virus 
(HPV)17, Hepatitis B Virus (HBV)18, Helicobacter pylori (H. 
pylori)19, Human Herpes Virus (HHV8)20, and Epstein Barr 
Virus (EBV)21. 
Although cancer incidence has been increasing in every part 
of  the world, there are huge inequalities between developed 
and developing countries. Age adjusted incidence rates 
remain highest in developed countries and mortality is 
relatively much higher in developing countries due to lack of  
early detection and access to treatment facilities8. Infections 
due to human papillomavirus and hepatitis B and C viruses 
significantly contribute to the burden of  cervical and liver 
cancers respectively on the African Continent8.The most 
common cancers in the African region are cervical, breast, 
liver and prostate as well as Kaposi’s sarcoma and non-
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Hodgkin’s lymphoma8.
Zambia is one of  the sub-Saharan African countries that 
has not been spared by the increasing burden of  cancers. 
Many lives can be saved if  appropriate investment is made 
in raising public awareness on the early signs and symptoms 
of  common cancers as well as implementation of  early 
detection strategies8. This study therefore sought to assess 
the epidemiology of  cancers in Zambia. 
Materials and Methods 
Study site
Zambia is located in the southern zone of  the African 
continent and lies between latitudes 8° and 18° south, 
and longitudes 22° and 34° east. The country has a total 
geographical area of  753,612km2,22.
Study design
We conducted a retrospective observational study using 
the Zambia National Cancer Registry (ZNCR) population 
based data from 2007 to 2014. ZNCR collects and keeps 
population based cancer data in Zambia. Sources of  data 
include Health Management Information System (HMIS), 
Government and private Hospital Registries, which are also 
linked from grass root level by health centres to ensure that 
all suspected cancer cases are referred to the hospitals. Other 
sources include death records, Community Health Workers 
(CHW) and Churches Health Organisation (CHAZ). The 
collected information include patient’s personal details 
(names, age, sex, date of  birth and residential address at 
diagnosis). Hospital details (hospital, consultant patient unit 
number), diagnostics, tumour and treatment details (site of  
primary, morphology, laterality, stage, grade of  tumour, basis 
of  diagnosis, date of  diagnosis, treatment indicators) as well 
as  death details (alive or dead, date of  death, cause(s) and 
place of  death).
ZNCR ensures that cancer registration data is stored 
securely, backed up and only accessible to authorised cancer 
registry staff  and researchers. All cancer notification forms 
or books are filed and locked in a secure place. Information 
request for data on cancers are made in writing to the 
Registrar and the Permanent Secretary at the Ministry of  
Health for approval. This study got formal administrative 
approval from the Cancer registry for data access, approved 
by both the University of  Zambia Biomedical Research 
Ethics Committee (UNZABREC) and the National Health 
Research Authority of  Zambia with reference number 003-
08-17.
Zambia Central Statistics Office (CSO) provided us with 
shapes files for provinces and districts as well as demographic 
data, which we used to determine prevalence and Age-
specific rates while World Standard Population23 was used 
to determine Standardised Incidence Rates (SIR).  Case 
fatality rate (CFR) was calculated as: . We used a Poisson 
Approximation for calculating 95% confidence intervals. 




Where the variance for the age-standardised rate was given 
by:
 
 is the number of  events in age group i in the study 
population
 is the incidence rate in the study population for the 
persons in age group i 
Pi is the number of  persons in age group i in the standard 
population.
Mapping of  the distribution of  cancers at district and 
provincial levels were done using Geographical Information 
System (ArcGIS) version 10.3.1, Redlands, CA. Some big 
districts in Zambia were split to form new districts for 
effective administrative purposes. New population figures 
for new districts were not available hence population figures 
for original districts were considered. For instance, districts 
such as Ikelenge, Zimba and Mafinga were still part of  the 
original districts namely, Mwinilunga, Kalomo and Isoka 
respectively during the study period hence; we considered 
cancer rates of  original districts in these new districts.
Sampling
Since our study was registry based, we considered all cancer 
cases in the Zambia National Cancer Registry database from 
2007 to 2014. We ,however,  excluded cancer cases not 
belonging to any of  the ten provinces in Zambia (i.e. not 
coded cases from any region in Zambia) for the purpose 
of  GIS mapping which required that cancer cases be 
linked to districts and provinces of  origin. In addition, we 
sampled and surveyed ten districts across Zambia to assess 
the incidence and prevalence of  cancer and determine risk 
factors contributing to escalating cancer cases.
Statistical Analyses
We used SPSS version 21 in our data analyses. Logistic 
regression model was used to determine the association 
between cancer and HIV while Pearson Correlation was used 
to determine the correlation coefficient.  We used a Poisson 
Approximation for calculating 95% confidence intervals.
Results
Distribution of cancers by region and province
During our study period from 2007 to 2014, a total of  
21,512 cancer cases were notified to ZNCR of  which 7,560 
(35.14%) were males and 13,952 (64.86%) were females. 
The four most prevalent types of  cancers were cervical 
(97.1/10000), prostate (22.1/100,000), breast (19.3/100,000) 
and Kaposis sarcoma (19.2/100,000). Cancers were 
widely distributed in Zambia with high prevalence (105-
281/100,000) concentrated in the southern zone comprising 
Eastern, Central, Lusaka, Western and Southern Provinces. 
The southern zone was divided into high prevalence and 
medium prevalence regions. Eastern and Lusaka Provinces 
formed the high prevalence region (126-281/100,000) 
while Central, Southern and Western Provinces formed the 
medium prevalence region (105-125/100,000). The northern 
zone comprising North Western, Copperbelt, Luapula, 
Northern and Muchinga Provinces had relatively low cancer 
prevalence of  78-104/100,000 population. 
By gender, cancers were more prevalent in females than in 
males in all the ten provinces with mean sex ratio F/M = 1.85. 
Table 1 shows the prevalence of  cancers by province and sex. 
The prevalence of  cancer in both males and females were 
more in Lusaka, Eastern and Central Provinces. However, 
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Table 1: Distribution of cancers (all types) in Zambia by Province
                              Prevalence Rate Per 100,000 Population
Province Total Males Females
Central 125 87 162
Copperbelt 97 51 143
Eastern 165 109 220
Luapula 84 66 102
Lusaka 281 212 349
Northern 90 69 118
Muchinga 78 59 97
North West 104 89 118
Southern 115 83 145
Western 114 84 142
Figure 1: Regional and provincial distribution of cancers in Zambia
Figure 2: Provincial distribution of cancers (all types) by sex
for males, the prevalence was also more in Western Province. 
In addition, Southern, Copperbelt and Western Provinces 
had more prevalence of  cancer in females
Figure 2 shows details of  provincial distribution of  cancers 
by sex.
Distribution of cancers by district
The distribution of  cancers at district level was similar to 
the zonal pattern at provincial level. Figure 3 shows the 
geographical distribution of  cancers by district in Zambia. 
Some districts such as Mafinga, Ikelenge and Zimba were 
still part of  the original districts namely Isoka, Mwinilunga 
and Kalomo respectively at the beginning of  our research 
period hence: are shown as combined districts in Table 2. 
Some big districts in Zambia were split to form new districts 
for effective administrative purposes. The prevalence of  
cancers in the original districts reflects cancer prevalence in 
the new districts.
Luangwa was the most cancer prevalent district in Zambia 
with the rate of  1,014 per 100,000 population,  followed 
by Kabwe with the prevalence rate of  379 per 100,000 
population. Lusaka was the third district with prevalence rate 
of  311 per 100,000, Monze ranked fourth with the rate of  
282 per 100,000, Mongu ranked fifth with prevalence rate of  
260 per 100,000, Katete ranked sixth with prevalence rate 
of  229 per 100,000 population and Chipata district ranked 
seventh with prevalence of  213 per 100,000 population. All 
these seven districts are from the southern zone. 
The four most cancer prevalent districts in the northern zone 
were Kasempa (193 / 100,000), Kasama (168 / 100,000), 
Ndola (165 /100,000) and Mansa (165 / 100,000 population). 
The least four cancer prevalent districts in Zambia were 
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Table 2: Ranked prevalence of cancers (all types) by district per 100,000 population
District Total Males Females District Total Males Females
Luangwa 1014 766 1257 Chinsali 90 52 127
Kabwe 379 251 499 Mkushi 88 57 120
Lusaka 311 233 387 Mwense 88 76 99
Monze 282 157 404 Luwingu 87 360 114
Mongu 260 176 337 Kitwe 82 52 113
Katete 229 142 313 Kaoma 80 62 96
Chipata 213 133 291 Sesheke 78 64 91
Kasempa 193 176 210 Isoka/ Mafinga 77 62 91
Kasama 168 118 217 Kafue 77 66 88
Ndola 165 76 252 Lukulu 77 37 114
Mansa 165 110 217 Chadiza 74 49 99
Choma 158 126 189 Samfya 70 74 67
Luanshya 156 77 234 Siavonga 70 49 90
Chongwe 155 123 187 Namwala 69 66 71
Petauke 153 102 202 Solwezi 65 60 71
Mumbwa 144 116 171 Kapiri Mposhi 61 32 89
Mbala 142 96 187 Chibombo 56 45 68
Livingstone 138 118 157 Nakonde 53 36 70
Zambezi 135 116 155 Sinazongwe 48 49 47
Mazabuka 126 86 165 Chama 48 47 48
Lundazi 120 86 153 Kalomo/ Zimba 45 34 47
Gwembe 113 80 145 Mpongwe 44 19 70
Mambwe 112 110 113 Nchelenge 43 30 55
Kalabo 111 91 130 Chililabombwe 40 19 61
Mufumbwe 110 97 124 Kalulushi 35 13 57
Mwinilunga/Ikelenge 107 73 141 Milenge 29 20 38
Nyimba 107 72 141 Mpulungu 29 14 43
Kabompo 106 97 116 Mungwi 27 19 35
Serenje 105 78 132 Kaputa 26 16 35
Chavuma 105 102 108 Shang’ombo 19 18 20
Mufulira 104 60 148 Chilubi 18 14 22
Mpika 102 82 122 Masaiti 17 17 17
Mporokoso 100 77 123 Lufwanyama 16 2 31
Kawambwa 95 78 110 Itezhi tezhi 16 17 14
Senanga 93 84 101 Kazungula 14 13 16
Chingola 93 53 133 Chienge 12 9 15
Lufwanyama (16 / 100,000), Itezhi tezhi (16 /100,000), 
Kazungula (14 / 100,000) and Chienge (12 / 100,000 
population) during the study period. Table 2 shows details 
of  ranked prevalence of  cancers by district per 100,000 
population.
With few exceptions of  districts such as Luwingu, Sinazongwe 
and Samfya where cancers were more prevalent in males 
than in females, most districts in Zambia had high cancer 
prevalence in females than in males. The trend in the total 
district pattern (see Figure 3) remained the same as cancer 
distribution by sex at district level (see Figure 4). The detailed 
geographical distribution of  cancers by sex at district level is 
shown in Figure 4.
Morbidity and mortality of cancers in Zambia 
Cervical cancer was the most prevalent cancer in Zambia 
followed by prostate cancer, breast cancer and Kaposi’s 
sarcoma. The prevalence rate of  cervical cancer was 97.1 
per 100,000 females and represented 34.3% of  all cancers 
in Zambia. In proportional terms, Kaposi’s sarcoma ranked 
second and represented 13.3%, prostate cancer ranked third 
and represented 7.7% while breast cancer ranked fourth and 
represented 6.8%. Myeloma and Other Pharynx were the 
least prevalent among other cancers; each represented 0.2% 
of  all cancers in Zambia. Table 3 shows details of  prevalence 
and proportions of  cancers in Zambia from 2007 to 2014.
Age specific rates, Standardised Incidence Rates (SIR) and 
the 95% confidence intervals (CI) for all cancers in Zambia 
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Male Female Both Sexes
Proportion (%)Cases Proportion (%) Cases Proportion (%)
Cervix Uteri 7389 97.1 7389 53 34.3
Kaposi’s Sarcoma 2891 19.2 1759 23.3 1132 8.1 13.4
Prostate 1651 22.1 1651 21.8 7.7
Breast 1469 19.3 41 0.5 1428 10.2 6.8
Eye 909 6.0 431 5.7 478 3.4 4.2
Non-Hodgkin Lympoma 665 4.4 358 4.7 307 2.2 3.1
Oesophagus 581 3.9 365 4.8 216 1.5 2.7
Large Bowel 539 3.6 278 3.7 261 1.9 2.5
Bladder 478 3.2 261 3.5 217 1.6 2.2
Liver 460 3.1 283 3.7 177 1.3 2.1
Other Skin 406 2.7 192 2.5 214 1.5 1.9
Stomach 395 2.6 210 2.8 185 1.3 1.8
Bone 252 1.7 130 1.7 122 0.9 1.2
Vulva/Vagina 246 3.2 246 1.8 1.1
Ovary 238 3.1 238 1.7 1.1
Kidney 171 1.1 80 1.1 91 0.7 0.8
Oral Cavity 168 1.1 95 1.3 73 0.5 0.8
Penis 166 2.2 166 2.2 0.8
Hodgkin Disease 151 1.0 99 1.3 52 0.4 0.7
Melanoma of the skin 145 1.0 56 0.7 89 0.6 0.7
Lung 135 0.9 90 1.2 45 0.3 0.6
Brain, Nervous System 126 0.8 69 0.9 57 0.4 0.6
Leukaemia 126 0.8 79 1 47 0.3 0.6
Larynx 125 0.8 102 1.3 23 0.2 0.6
Uterus 115 1.5 115 0.8 0.5
Pancreas 102 0.7 61 0.8 41 0.3 0.5
Corpus Uteri 95 0.6 95 0.7 0.4
Thyroid 92 0.6 30 0.4 62 0.4 0.4
Nasopharynx 85 0.6 51 0.7 34 0.2 0.4
Myeloma 45 0.3 27 0.4 18 0.1 0.2
Other Pharynx 42 0.3 29 0.4 13 0.1 0.2
Others 1054 7.0 567 7.5 487 3.5 4.9
Totals 21512 142.8 7560 100 13952 100 100
Fig 3: Distribution of cancers (all types) by district
are shown in Table 4. Rates were adjusted 
using the world standard population [23]. 
The standardised incidence rates and 95% 
confidence intervals for the top four cancers 
in Zambia were: cervix uteri (186.3; 95% CI 
= 181.77 – 190.83), prostate (60.03; 95% CI = 
57.03 – 63.03), breast (38.08; 95% CI = 36.0 – 
40.16) and Kaposi’s sarcoma (26.18; 95% CI = 
25.14 – 27.22). Peaks of  age specific rates were 
in the age range 40 – 49 years for cervix uteri, 
60 – 69 years for prostate cancer, and 40 – 49 
years for breast cancer and 30 – 39 years for 
Kaposi’s sarcoma.
Like other diseases, various forms of  cancers 
have been classified in the International 
Classification of  Diseases known as ICD10. 
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Table 4: Standardised Incidence Rates (SIR) for all cancers in Zambia, 2007 - 2014
CANCER TYPE Age-specific Incidence Rate  per 100,000 population SIR all 
ages
95%  CI
0-9yr 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ Lower Upper
Cervix Uteri 0 0.07 5.5 23.41 49.68 46.11 39.78 14.09 7.67 186.3 181.77 190.83
Prostate 0 0 0 0.07 0.89 5.52 22.83 21.92 8.8 60.03 57.03 63.03
Breast 0 0.03 1.29 4.03 9.46 8.53 9.09 4.38 1.26 38.08 36 40.16
Kaposi’s Sarcoma 0.35 0.65 3.58 7.66 7.42 3.17 1.82 0.64 0.88 26.18 25.14 27.22
Oesophagus 0.01 0.01 0.11 0.64 1.6 1.67 2.49 1.45 0.4 8.38 7.66 8.38
Eye 0.7 0.1 0.57 1.97 2.27 1.06 0.85 0.25 0.52 8.29 7.69 8.89
Bladder 0.01 0.02 0.12 0.34 0.78 1.36 2.94 1.41 0.46 7.45 6.74 8.16
Large Bowel 0 0.03 0.32 0.64 1.63 1.53 1.93 0.87 0.24 7.19 6.54 7.84
Non-Hodgkin Lympoma 0.31 0.45 0.51 0.8 1.46 1.33 1.28 0.48 0.2 6.82 6.23 7.41
Vulva/Vagina 0 0.01 0.31 0.8 1.61 1.22 1.23 0.46 0.3 5.94 5.14 6.74
Liver 0.02 0.09 0.27 0.56 1.21 1.22 1.3 0.83 0.36 5.86 5.28 6.44
Ovary 0.01 0.14 0.41 0.47 1.56 1.34 0.98 0.62 0.14 5.66 4.88 6.44
Stomach 0.01 0.02 0.12 0.41 0.93 1.23 1.53 1.04 0.32 5.61 5.02 6.2
Other Skin 0.05 0.08 0.28 0.53 0.81 1 1.26 0.69 0.38 5.07 4.53 5.61
Penis 0.02 0 0.03 0.26 0.98 1.28 1.38 0.58 0.41 4.93 4.13 5.73
Uterus 0 0.01 0.12 0.26 1.04 0.61 0.64 0.1 0.11 2.89 2.33 3.45
Corpus Uteri 0 0 0.06 0.12 0.42 0.85 1.15 0.2 0.07 2.87 2.26 3.48
Melanoma of the skin 0 0.02 0.02 0.1 0.28 0.48 0.88 0.39 0.09 2.26 1.87 2.65
Bone 0.1 0.38 0.25 0.22 0.36 0.22 0.52 0.12 0.07 2.25 1.92 2.58
Oral Cavity 0.04 0.05 0.08 0.13 0.36 0.55 0.63 0.34 0.07 2.24 1.87 2.61
Larynx 0.01 0 0.01 0.01 0.24 0.45 0.99 0.35 0.07 2.14 1.75 2.53
Lung 0 0 0.03 0.07 0.2 0.55 0.72 0.39 0.16 2.12 1.75 2.49
Pancreas 0 0 0.02 0.06 0.34 0.5 0.27 0.19 0.06 1.45 1.16 1.75
Hodgkin Disease 0.08 0.19 0.13 0.15 0.32 0.19 0.2 0.05 0.04 1.34 1.09 1.59
Thyroid 0 0.04 0.07 0.06 0.2 0.27 0.38 0.11 0.09 1.22 0.95 1.49
Kidney 0.45 0.09 0.01 0.1 0.13 0.12 0.11 0.07 0.07 1.16 0.95 1.37
Brain, Nervous System 0.16 0.08 0.1 0.08 0.23 0.2 0.18 0.09 0.02 1.13 0.9 1.36
Nasopharynx 0.03 0.05 0.04 0.11 0.21 0.25 0.29 0.02 0 0.99 0.75 1.23
Leukaemia 0.24 0.21 0.04 0.04 0.09 0.06 0.04 0.05 0 0.78 0.62 0.94
Other Pharynx 0 0.01 0.01 0.01 0.07 0.11 0.29 0.09 0.06 0.65 0.58 0.72
Myeloma 0 0.01 0.01 0.04 0.07 0.28 0.16 0.04 0.02 0.63 0.43 0.83
Others 0.35 0.52 0.84 1.07 1.98 2.47 2.88 1.32 0.68 12.11 11.29 12.93
Figure 4: Distribution of can-
cers all types by sex
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Cases Deaths Case Fatality 
Rate (%)
Leukaemia C91-C95 126 48 38.1
Pancreas C25 102 37 36.3
Lung C33-C34 135 45 33.3
Brain, Nervous System C70-C72 126 38 30.2
Kidney C64 171 38 22.2
Liver C22 460 91 19.8
Stomach C16 395 78 19.7
Oesophagus C15 581 113 19.4
Bladder C67 478 90 18.8
Ovary C56 238 44 18.5
Myeloma C90 45 8 17.8
Nasopharynx C11 85 15 17.6
Corpus Uteri C54 95 16 16.8
Bone C40-C41 252 40 15.9
Melanoma of the Skin C43 145 21 14.5
Non-Hodgkin Lympoma C82,C85,C96 665 89 13.4
Prostate C61 1651 215 13.0
Large Bowel C18-C21 539 68 12.6
Kaposi’s Sarcoma C46 2891 332 11.5
Thyroid C73 92 10 10.9
Larynx C32 125 12 9.6
Hodgkin Disease C81 151 14 9.3
Uterus C55 115 9 7.8
Breast C50 1469 113 7.7
Cervix Uteri C53 7389 543 7.3
Penis C60 166 12 7.2
Oral Cavity C00-C06 169 12 7.1
Other Skin C44 406 25 6.2
Eye C69 909 53 5.8
Vulva/Vagina C51-C52 246 12 4.9
Other Pharynx C09-C10, C12-C14 42 2 4.8
Table 5 shows details of  ICD10 codes for cancers, their 
mortality and case fatality rates (CFR). Leukaemia (38.1%) 
and pancreatic cancer (36.3%) have the highest CFR among 
cancers in Zambia followed by lung cancer (33.3%) and 
brain, nervous system (30.2%). 
Although CFR has been very high in Leukaemia, pancreatic 
cancer, lung cancer and cancers of  the brain and nervous 
system, cancer morbidity rates were high in cervical cancer, 
prostate cancer, Kaposi’s sarcoma, breast cancer and 
oesophageal cancer. During our study period 2007 to 2014, 
there were 543 cervical cancer deaths (CFR =7.3). Prostate 
cancer ranked second with 215 deaths (CFR=13) followed 
by Kaposis’ sarcoma with 332 deaths (CFR=11.5), then 
breast cancer with 113 deaths (CFR=7.7) and oesophagus 
cancer with 113 deaths (CFR=19.4). 
Association between cancers and HIV in Zambia
The cancer population in Zambia has high HIV prevalence. 
Results of  the logistic regression analysis and Pearson 
correlation indicated a strong association between cancer 
and HIV with p- value of  0.000 and correlation coefficient 
of  0.818. Cancer cases, HIV positive cases and percentage 
of  HIV positive cancer cases are shown in Table 6. 
Discussion
This study assessed the incidence and prevalence of  major 
cancers in the Zambian population as well as the associated 
risk factors. The study makes an important contribution 
in showing the incidence and prevalence of  cancers in 
Zambia, which will be important for primary and secondary 
prevention methods.
Although cancers were widely distributed in Zambia, this 
study established that cancers were more prevalent in the 
southern zone than the northern zone. The southern zone 
comprised the high   and medium prevalence  regions. 
Lusaka and Eastern provinces with very high cancer 
prevalent districts such as Luangwa, Katete, Chipata and 
Lusaka formed the belt of  the high prevalence region while 
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Table 6: Association between cancers and HIV in Zambia, 2007 – 2014





C00-C06 Oral Cavity 169 20 12
C09-C10, C12-C14 Other Pharynx 42 4 10
C11 Nasopharynx 85 22 26
C15 Oesophagus 581 71 12
C16 Stomach 395 41 10
C18-C21 Large Bowel 539 60 11
C22 Liver 460 43 9
C25 Pancreas 102 6 6
C32 Larynx 125 14 11
C33-C34 Lung 135 12 9
C40-C41 Bone 252 6 2
C43 Melanoma of the skin 145 11 8
C44 Other Skin 406 65 16
C46 Kaposi’s Sarcoma 2891 1734 60
C50 Breast 1469 169 12
C51-C52 Vulva/Vagina 246 58 24
C53 Cervix Uteri 7389 1331 18 0.818 0.000
C54 Corpus Uteri 95 8 8
C55 Uterus 115 14 12
C56 Ovary 238 25 11
C60 Penis 166 29 17
C61 Prostate 1651 99 6
C64 Kidney 171 4 2
C67 Bladder 478 22 5
C69 Eye 909 154 17
C70-C72 Brain, Nervous System 126 10 8
C73 Thyroid 92 8 9
C81 Hodgkin Disease 151 31 21
C82,C85,C96 Non-Hodgkin Lympoma 665 161 24
C90 Myeloma 45 3 7
C91-C95 Leukaemia 126 5 4
C07-C08, C17,… Others 1054 97 9
Totals 21512 4337 20
Central, Southern and Western provinces with high cancer 
prevalent districts such as Kabwe, Mongu and Monze among 
others formed the medium prevalence region. Although the 
northern zone had relatively low prevalence of  cancers, there 
were notable districts such as Kasempa, Kasama, Ndola and 
Mansa with relatively high prevalence rates. 
Some studies argue that the observed geographic variation 
in cancer distribution is due to differences in the availability 
of  cancer screening and detection facilities as well as health 
seeking behaviour24-26. Our study however has established 
that geographic location played a big role in the pattern of  
cancer distribution in Zambia. This observation was made 
after mapping cancer cases based on patients’ residential 
addresses. Distinct patterns were geographically displayed 
implying that geographic distribution played a role. 
This study also observed that the northern belt of  Zambia 
practices childhood male circumcision unlike the southern 
belt. Previous studies have shown that male circumcision 
reduces the spread of  HPV, which causes cervical cancer29. 
Low uptake of  childhood circumcision in the southern 
region could therefore be linked with the observed high 
prevalence of  cervical cancer in that region. Furthermore, 
lack of  awareness and education of  cervical cancer and 
HPV coupled with low screening uptake led to the spread 
of  human papilloma virus (HPV) which causes cervical 
cancer24. 
Sex disaggregated data showed that cancers in Zambia 
affected more females than males in the ratio 64.86% to 
35.14% (F/M = 1.85). This is mostly because of  the high 
prevalence of  cervical cancer in Zambian women. This study 
identified cervical cancer, prostate cancer, breast cancer and 
Kaposi’s sarcoma as the top four most prevalent cancers 
in Zambia. Cervical cancer, with standardised incidence 
rate of  186.3 per 100,000 females was the leading cause of  
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morbidity and mortality among cancers in Zambian women. 
This is contrary to other studies, which established that 
cervical cancer was the third leading cause of  cancer-related 
deaths in developing countries, which is not the case with 
Zambia30. Age standardized incidence rates (Table 4) show 
that cervical cancer rates peak around the age range of  40-49 
years implying that this age group is the high-risk group for 
cervical cancer in Zambia.
The prevalence of  HPV infection was 5% in North America 
and 21% in Africa. This is as a result of  high screening uptake 
and vaccine which are  more available in the west compared 
to Africa24,27. In sub-Saharan Africa, cervical cancer incidence 
has been influenced by the high prevalence of  HIV infection, 
which has been found to promote progression of  cancerous 
lesions30. Cervical cancer incidence rates decreased by as 
much as 4% annually, and 70% overall in developed countries 
where screening programs were introduced several decades 
ago32,33. The observed adjusted incidence rates of  cervical 
cancer in Zambia is similar to observed trends in Zimbabwe 
and Uganda27,4,35.
Prostate cancer was the second most prevalent cancer after 
cervical cancer and number one cancer in Zambian men 
with adjusted standardised incidence rate of  60.03 per 
100,000 males. These results are similar to the results of  
other studies, which indicated that prostate cancer was the 
most prevalent cancer in men30. In this study, prostate cancer 
peak ranged from 60 – 69 years. These results indicate that 
prostate cancer is more prevalent in ageing men. 
Breast cancer ranked third among cancers in Zambia and 
second in women after cervical cancer. It had an adjusted 
standardised incidence rate of  38.08 per 100,000 females. 
Breast cancer peak ranged from 40 – 49 years, which is 
the productive age group for women. On the global scale, 
breast cancer is the leading cause of  cancer-related deaths 
among females. It is highest in the United States and Western 
Europe while Africa and Asia have relatively low rates30,36. 
Risk factors for breast cancer include weight gain after age 
18 years, excess body weight (for postmenopausal breast 
cancer), use of  menopausal hormone therapy (MHT), 
physical inactivity, alcohol consumption, and reproductive 
and hormonal factors, such as a long menstrual history, and 
nulliparity or later age at first birth. Risk factors for breast 
cancer also include inherited changes in BRCA1 and BRCA2 
genes37,38. On the other hand, breastfeeding decreases the 
risk of  breast cancer38.
The distribution of  some cancers in Zambia followed the 
trend of  HIV epidemiology. This study established a strong 
positive association between cancers and HIV with p-value 
of  0.000. These results indicate that HIV is a risk factor of  
cancers in Zambia. Some cancers such as Kaposi’s sarcoma 
are HIV defining malignancies. Kaposi’s sarcoma ranked 
fourth among cancers in Zambia with adjusted incidence 
rate of  26.18 per 100,000 population. Kaposi’s sarcoma peak 
ranged from 30 – 39 years. This study observed that Kaposi’s 
sarcoma was more prevalent in males than in females (see 
Table 3). The incidence of  Kaposi’s sarcoma is higher in Sub-
Saharan Africa than in developed countries. The endemic 
African form of  Kaposi’s sarcoma was reported in the 
1960s39, but with the emergence of  HIV/AIDS, an atypical 
aggressive type was reported in most African countries40,41,42. 
Although morbidity rate was high in cervical, prostate and 
breast cancers as well as oesophageal cancer and Kaposi’s 
sarcoma, case fatality rate was moderate in these cancers 
compared to Leukaemia, pancreatic cancer, lung cancer and 
cancers of  the brain and nervous system where case fatality 
rates were high. 
This study had some limitations, firstly, the missing 
information in the database due to challenges in active 
cancer surveillance made us leave some patients’ files, as 
they could not be linked to districts of  origin. Secondly, the 
Zambia National Cancer Registry had huge backlog of  data 
due to understaffing. This brought about the adjustment of  
our study from 2007 - 2017 to 2007 -  2014 period. Lastly, 
registry based studies have challenges to provide precise 
data as registries data capturing system do not always suit all 
study designs. ZNCR did not fully capture risk factors for 
all cancers hence; we could not critically determine all risk 
factors in this study.
In conclusion, the widespread distribution of  cancers with 
high prevalence in the southern zone was perpetrated by 
lifestyle and sexual culture as well as geography. Traditional 
male circumcision known to prevent STIs is practiced in the 
northern belt (particularly North Western Province) and not 
the southern belt. The seven most cancer prevalent districts 
in Zambia were Luangwa, Kabwe, Lusaka, Monze, Mongu, 
Katete and Chipata. Cervical cancer, prostate cancer, breast 
cancer and Kaposi’s sarcoma were the four most prevalent 
cancers as well as major causes of  cancer related deaths in 
Zambia; although Leukaemia and pancreatic cancer had, the 
highest case fatality rate. Most cancers in Zambia are HIV 
defining malignancies and their upward trend is due to the 
increase in HIV cases.  Changing the lifestyle and sexual 
culture (multiple sexual partners) would greatly help in the 
prevention of  rampant spread of  HPV, HIV, HBV and EBV 
among others which would result in the reduction of  cancer 
cases in Zambia.  Furthermore, intensifying cancer screening 
and early detection countrywide would help to drastically 
reduce cancer prevalence in Zambia over time.
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